|
1
|
Liu B and Hong JS: Role of microglia in
inflammation-mediated neurodegenerative diseases: mechanisms and
strategies for therapeutic intervention. J Pharmacol Exp Ther.
304:1–7. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moon DO, Choi YH, Kim ND, Park YM and Kim
GY: Anti-inflammatory effects of β-lapachone in
lipopolysaccharide-stimulated BV2 microglia. Int Immunopharmacol.
7:506–514. 2007.
|
|
3
|
Kubes P and McCafferty DM: Nitric oxide
and intestinal inflammation. Am J Med. 109:150–158. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee AK, Sung SH, Kim YC and Kim SG:
Inhibition of lipopolysaccharide-inducible nitric oxide synthase,
TNF-α and COX-2 expression by sauchinone effects on I-κBα
phosphorylation, C/EBP and AP-1 activation. Br J Pharmacol.
139:11–20. 2003.
|
|
5
|
Palladino MA, Bahjat FR, Theodorakis EA
and Moldawer LL: Anti-TNF-α therapies: the next generation. Nat Rev
Drug Discov. 2:736–746. 2003.
|
|
6
|
Kalmar B, Kittel A, Lemmens R, Kornyei Z
and Madarasz E: Cultured astrocytes react to LPS with increased
cyclooxygenase activity and phagocytosis. Neurochem Int.
38:453–461. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park HJ, Kim IT, Won JH, Jeong SH, Park
EY, Nam JH, Choi J and Lee KT: Anti-inflammatory activities of
ent-16αH,17-hydroxy-kauran-19-oic acid isolated from
the roots of Siegesbeckia pubescens are due to the
inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages
via NF-κB inactivation. Eur J Pharmacol. 558:185–193.
2007.PubMed/NCBI
|
|
8
|
Surh YJ, Chun KS, Cha HH, Han SS, Keum YS,
Park KK and Lee SS: Molecular mechanisms underlying chemopreventive
activities of anti-inflammatory phytochemicals: down-regulation of
COX-2 and iNOS through suppression of NF-κB activation. Mutat Res.
480–481:243–268. 2001.PubMed/NCBI
|
|
9
|
Bredt DS and Snyder SH: Nitric Oxide: a
physiologic messenger molecule. Annu Rev Biochem. 63:175–195. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xie Q and Nathan C: The high-output nitric
oxide pathway: role and regulation. J Leukoc Biol. 56:576–582.
1994.PubMed/NCBI
|
|
11
|
Lappas M, Permezel M, Georgiou HM and Rice
GE: Nuclear factor kappa B regulation of proinflammatory cytokines
in human gestational tissues in vitro. Biol Reprod. 67:668–673.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Karin M: The beginning of the end: IκB
kinase (IKK) and NF-κB activation. J Biol Chem. 274:27339–27342.
1999.
|
|
13
|
Maciejewski R, Burdan F, Burski K, Madej
B, Ziemiakowicz R, Dabrowski A and Wallner G: Selected biochemical
parameters and ultrastructural picture of pancreas due to
Ulinastatin treatment of experimental acute pancreatitis. Exp
Toxicol Pathol. 56:305–311. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tani T, Aoki H, Yoshioka T, Lin KJ and
Kodama M: Treatment of septic shock with a protease inhibitor in a
canine model: a prospective, randomized, controlled trial. Crit
Care Med. 21:925–930. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Masuda T, Sato K, Noda C, Ikeda KM,
Matsunaga A, Ogura MN, Shimizu K, Nagasawa H, Matsuyama N and Izumi
T: Protective effect of urinary trypsin inhibitor on myocardial
mitochondria during hemorrhagic shock and reperfusion. Crit Care
Med. 31:1987–1992. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yano T, Anraku S, Nakayama R and Ushijima
K: Neuroprotective effect of urinary trypsin inhibitor against
focal cerebral ischemia-reperfusion injury in rats. Anesthesiology.
98:465–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shin IW, Jang IS, Lee SM, Park KE, Ok SH,
Sohn JT, Lee HK and Chung YK: Myocardial protective effect by
ulinastatin via an anti-inflammatory response after regional
ischemia/reperfusion injury in an in vivo rat heart model. Korean J
Anesthesiol. 61:499–505. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Molor-Erdene P, Okajima K, Isobe H, Uchiba
M, Harada N and Okabe H: Urinary trypsin inhibitor reduces
LPS-induced hypotension by suppressing tumor necrosis factor-α
production through inhibition of Egr-1 expression. Am J Physiol
Heart Circ Physiol. 288:H1265–H1271. 2005.PubMed/NCBI
|
|
19
|
Tanaka Y, Maehara S, Sumi H, Toki N,
Moriyama S and Sasaki K: Purification and partial characterization
of two forms of urinary trypsin inhibitor. Biochim Biophys Acta.
705:192–199. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanai T, Ishiwata T, Kobayashi T, Sato H,
Takizawa M, Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N,
Nishiyama M, Hatai Y, Asano Y, Kobayashi T, Takeshita S and
Nonoyama S: Ulinastatin, a urinary trypsin inhibitor, for the
initial treatment of patients with Kawasaki disease: a
retrospective study. Circulation. 124:2822–2828. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao C, Li R and Wang S: Ulinastatin
protects pulmonary tissues from lipopolysaccharide-induced injury
as an immunomodulator. J Trauma Acute Care Surg. 72:169–176.
2012.PubMed/NCBI
|
|
22
|
Inoue K, Takano H, Shimada A, Yanagisawa
R, Sakurai M, Yoshino S, Sato H and Yoshikawa T: Urinary trypsin
inhibitor protects against systemic inflammation induced by
lipopolysaccharide. Mol Pharmacol. 67:673–680. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M,
Ichimaru T, Fujita I, Tasaki H and Miyazaki S: Ulinastatin, an
elastase inhibitor, inhibits the increased mRNA expression of
prostaglandin H2 synthase-type 2 in Kawasaki disease. J
Infect Dis. 181:1101–1109. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakamura H, Abe S, Shibata Y, Sata M, Kato
S, Saito H, Hino T, Takahashi H and Tomoike H: Inhibition of
neutrophil elastase-induced interleukin-8 gene expression by
urinary trypsin inhibitor in human bronchial epithelial cells. Int
Arch Allergy Immunol. 112:157–162. 1997. View Article : Google Scholar
|
|
25
|
Aosasa S, Ono S, Mochizuki H, Tsujimoto H,
Ueno C and Matsumoto A: Mechanism of the inhibitory effect of
protease inhibitor on tumor necrosis factor alpha production of
monocytes. Shock. 15:101–105. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qiu X, Ji S, Wang J, Li H, Xia T, Pan B,
Xiao S and Xia Z: The therapeutic efficacy of Ulinastatin for rats
with smoking inhalation injury. Int Immunopharmacol. 14:289–295.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu CE, Zhang MY, Zou CW and Guo L:
Evaluation of the pharmacological function of ulinastatin in
experimental animals. Molecules. 17:9070–9080. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Crofford LJ, Lipsky PE, Brooks P, Abramson
SB, Simon LS and van de Putte LB: Basic biology and clinical
application of specific cyclooxygenase-2 inhibitors. Arthritis
Rheum. 43:4–13. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hinz B, Brune K and Pahl A: Prostaglandin
E2 upregulates cyclooxygenase-2 expression in
lipopolysaccharide-stimulated raw 264.7 macrophages. Biochem
Biophys Res Commun. 272:744–748. 2000.
|
|
30
|
Ohshima H and Bartsch H: Chronic
infections and inflammatory processes as cancer risk factors:
possible role of nitric oxide in carcinogenesis. Mutat Res.
305:253–264. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Salerno L, Sorrenti V, Di Giacomo C, Romeo
G and Siracusa MA: Progress in the development of selective nitric
oxide synthase (NOS) inhibitors. Curr Pharm Des. 8:177–200. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Salvemini D, Misko TP, Masferrer JL,
Seibert K, Currie MG and Needleman P: Nitric oxide activates
cyclooxygenase enzymes. Proc Natl Acad Sci USA. 90:7240–7244. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jun CD, Choi BM, Kim HM and Chung HT:
Involvement of protein kinase C during taxol-induced activation of
murine peritoneal macrophages. J Immunol. 154:6541–6547.
1995.PubMed/NCBI
|
|
34
|
White KE, Ding Q, Moore BB, Peters-Golden
M, Ware LB, Matthay MA and Olman MA: Prostaglandin E2
mediates IL-1β-related fibroblast mitogenic effects in acute lung
injury through differential utilization of prostanoid receptors. J
Immunol. 180:637–646. 2008.PubMed/NCBI
|
|
35
|
Petrova TV, Akama KT and Van Eldik LJ:
Cyclopentenone prostaglandins suppress activation of microglia:
down-regulation of inducible nitric oxide synthase by
15-deoxy-Δ12,14-prostaglandin J2. Proc Natl
Acad Sci USA. 96:4668–4673. 1999.PubMed/NCBI
|
|
36
|
Ye SM and Johnson RW: Regulation of
interleukin-6 gene expression in brain of aged mice by nuclear
factor κB. J Neuroimmunol. 117:87–96. 2001.
|
|
37
|
Baeuerle PA and Baltimore D: NF-κB: ten
years after. Cell. 87:13–20. 1996.
|
|
38
|
Dijkstra G, Moshage H and Jansen PL:
Blockade of NF-κB activation and donation of nitric oxide: new
treatment options in inflammatory bowel disease? Scand J
Gastroenterol Suppl. 236:37–41. 2002.
|
|
39
|
Simmonds RE and Foxwell BM: Signalling,
inflammation and arthritis: NF-κB and its relevance to arthritis
and inflammation. Rheumatology. 47:584–590. 2008.
|
|
40
|
Wang H, Sun X, Gao F, Zhong B, Zhang YH
and Sun Z: Effect of ulinastatin on growth inhibition, apoptosis of
breast carcinoma cells is related to a decrease in signal
conduction of JNk-2 and NF-κB. J Exp Clin Cancer Res.
31:22012.PubMed/NCBI
|
